Research & Development: Page
-
PharmaVoice Team/PharmaVoice
Moving Science Forward -- Dr. Russell M. Medford
By Kim Ribbink With a pioneering spirit that has led him to tackle emerging fields of science, Russell M. Medford, M.D., Ph.D., is striving to ensure that AtheroGenics, the company he cofounded in 1993, is creating breakthrough medications for chronic inflammation. March 2007 Entrepreneurial spir...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Dr. Lou Barbato Tikvah Names VP, Clinical R&D, and Chief Medical Officer Atlanta-based Tikvah Therapeutics has named Lou Barbato, M.D., as VP, clinical research and development, and chief medical officer. Tikvah acquires, develops, and commercializes novel therapeutics related to ...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
E-Media
Thomson Scientific Expands Pharmaceutical Regulatory Intelligence Coverage Thomson Scientific announces that three new country modules, India, Israel, and Turkey, are now available in IDRAC, the global pharmaceutical regulatory intelligence database. IDRAC is recognized by regulatory professional...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
What's New
CommonHealth Celebrates Opening Of Paris Office The move is designed to allow CommonHealth to broaden its offerings to an increasingly global clientele. CommonHealth has opened an office in Paris. The move is designed to allow CommonHealth to broaden its offerings to an increasingly global client...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
March 15-16 Prescription Drug Pricing InterContinental The Barclay, New York PharmaVOICE subscribers are eligible for a $200 discount; register using priority code 656PHVC. For more information, contact Edward Santelices, American Conference Institute, at 212-352-3220, ext. 239, e-mail e.santelic...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Leadership development is a concern for all executive management teams, no matter the size of their company or their business model. It’s vitally important to have processes in place that foster talent development for the next generation of leaders. The subject of this month’s Forum had been on t...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
UpFront
Movers & Shakers HBA Honorees Woman of the Year, Honorable Mentor, and Star Volunteer Meryl Zausner, VP and CFO of Novartis Oncology, has been named as 2007 Woman of the Year by The Healthcare Businesswomen’s Association. Ms. Zausner was a founding member of the Novartis Oncology global busin...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Raise Your Voice -- Letters
Site Value I think most agree the PI/coordinator/patient relationship is key to enrollment and most importantly retention. Therefore PROs should be viewed in the context of their value added to each site that agrees to participate in a study as opposed to being viewed as an added value to the stu...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
CME: Measuring the Impact
By Denise Myshko Outcomes assessment of continuing education can help determine whether there is a change in participants’ knowledge and performance. March 2007 Barbara Winkelman CME LLC Over time, there is going to be a change in how CME is delivered and how outcomes are measured; there will be ...
By Denise Myshko • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Drug Counterfeiting Creates Need for RFID in European Markets The use of radio frequency identification (RFID) by Europe’s pharmaceutical industry continues to be driven by increasing counterfeit products in the market. Such counterfeiting is largely due to deficiencies in the supply chain and th...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
A New Era in the Science of Aging
By Cynthia Borda Older Americans face new and growing challenges in managing chronic diseases, which are now the leading causes of death among people older than the age of 65. Every seven seconds someone in the United States is celebrating a 60th birthday. This trend began Jan. 1, 2006, and will ...
By Cynthia Borda • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Master Plan: The Making of a Successful Publication Strategy
By Elisabeth Pena Villarroel Publication planning is an essential part of the drug-development process. The results of the long, labor-intensive years of a clinical trial are announced to the industry and medical professionals through publication in medical journals. Preparing trial results for p...
By Elisabeth Pena Villarroel • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Global Connections
By Taren Grom, Editor Global outsourcing, as it relates to international sponsor/supplier relationships, is constantly changing and growing. Pharmaceutical companies and their partners can gain significant competitive advantages through global outsourcing when sound business practices are applied...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Contributed by James Rogers Merging Clinical-Trials Safety and Pharmacovigilance The Winds of change in safety monitoring In November 2003, Mark B. McClellan, M.D., Ph.D., a former commissioner with the Food and Drug Administration, made the comment: “…there is no such thing as a completely safe ...
By James Rogers • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Raise Your Voice -- Letters
The Future of eClinical Recently, I had the opportunity to participate in an eClinical conference sponsored by etrials Inc. Clearly, among the participants at the event — both sponsors and trial partners –there was an underlying consensus that we understand the benefits of real-time data, know th...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
On the Cover The age of personalized medicine The study of genomics holds promise for helping to identify better drug targets and guiding companies in designing trials. The hope is that pharmacogenomics will lead to more targeted therapies. Features Patient recruitment marketing Patient recruitme...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Is there anything more personal than healthcare? Whether we are talking about medical records or medicine — personalization is coming into vogue, albeit with a caveat on privacy protection. According to a recent Wall Street Journal Online/Harris Interactive Health-Care poll, when it comes to the ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
PharmaTrax Sales, Marketing, and R&D Trends from Industry Analysts Scientific Expertise and Good Value Are Important When Choosing a CRO The primary factors pharmaceutical and biotechnology companies consider when selecting a CRO are the strength of its scientific expertise and the cost/value...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Registering Safety
By Kim Ribbink As the emphasis on drug development shifts toward improving risk management, new tools have emerged to evaluate safety both pre- and postapproval. Increasingly, companies are looking at patient registries as an integral part of their safety arsenal. Drug safety has become the focal...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Already 2007 is shaping up to be an interesting time. A new Congress, shifting demographics, regulatory restrictions, and other factors are sure to keep industry leaders on their toes. In early December, Pfizer’s two big announcements made headlines: first, a major reduction in its salesforce, th...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
New Electronic and Web-based Applications, Sites, and Technologies Phase Forward Expands Clinical-Trials Signal Detection System Phase Forward has unveiled a new version (2.0) of its clinical trials signal detection system — CTSD. The CTSD system enables clinical safety and medical monitoring sta...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
January 16-17 Pharma Pricing Strategies Radisson SAS, Rome For more information, contact Martin Manik, Jacob Fleming Group, at 42-12-5825-2729, e-mail [email protected], or visit jacobfleming.com. January 16-18 Pharmaceutical Leaders’ Summit Delray Beach Marriott, Delray Beach, Fla. F...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Is EDC the next CDMS?
VIEW on Data Management Is EDC the next CDMS? The lines between EDC and CDMS continue to blur as technology catches up with practicality and the need for cleaner data faster. Glen de Vries Glen de Vries, Cofounder and Chief Technology Officer of Medidata Solutions Worldwide, discusses why EDC is ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
EDC VS. CDM -- Choosing A Data-Collection Model
Conducting clinical trials is a highly specialized business that requires highly specific supporting software. The combination of complex functional and technical requirements, along with stringent regulatory requirements, means that standard cross-industry applications are rarely adequate. data ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
November 15 Turn Market Research into a Competitive Advantage McCann Erickson Building, New York For more information, contact Laura DeGroot, Healthcare Marketing & Communications Council, at 610-868-8299, e-mail [email protected], or visit hmc-council.org. November 15-16 International Pa...
By PharmaVoice Team • Jan. 2, 2008
Previous
